

PERSONAL INFORMATION



PAOLO CAMELI

📍 Strada di Malizia, 27, Siena, 53100, Italy

☎️ +393297856833

✉️ paolo.cameli@unisi.it

🌐 <https://scholar.google.com/citations?user=3xToyVEAAAAAJ&hl=it>

ScopusID: 55490604400; ORCID: 0000-0001-8639-2882; WoS ResearcherID: AAN-8345-2020

Sex Male | Date of birth 18/12/1988 | Nationality Italian

University
☐ Full professor
☒ Associate Professor
☐ Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

Overview

Scientific Profile: Paolo Cameli completed his medical university training course at the universities of Siena and Florence and is currently actively involved in national and international (ERS, ERN, WASOG) research groups. His main lines of research are focused on severe asthma and interstitial lung diseases, dealing specifically with the identification and validation in the clinical and biological field of markers of severity, prognosis and response to treatment. He had the merit of coordinating a research group involving various professional figures (doctors, biologists and biostatisticians), in order to contribute to the knowledge on the markers of exhaled breath, bronchoalveolar lavage and serum, analyzed through methods of molecular, cellular and - omics. These studies are mainly focused on rare lung diseases and on the different endotypes of severe asthma. He is author / co-author of over 170 publications in international journals with impact factor and peer-reviewed and participates as coordinator or investigator in numerous national and international research projects. He is reviewer and member of the editorial board of numerous international journals in the respiratory diseases and immunology field.

WORK EXPERIENCE

01/12/2024-ongoing	Associate Professor in Respiratory Diseases Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena.
01/12/2021-30/11/2024	Senior Researcher in Respiratory Diseases Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena. Full-time contract, definite time (3 years)
01/04/2020- 30/11/2021	Respiratory physician Respiratory Diseases Unit, Department of Medical Sciences, Azienda Ospedaliera Universitaria Senese
01/03/2020-31/03/2020	Medical Scholarship Respiratory Diseases Unit, Department of Medical Sciences, Azienda Ospedaliera Universitaria Senese
01/02/2019–31/01/2020	Temporary Research Fellow Respiratory Diseases and Lung Transplantation Unit, Department of Medicine, Surgery and Neurosciences, University of Siena

EDUCATION AND TRAINING

09/12/2021-09/03/2023	Second level Master Course in Rare Diseases University of Firenze
02/10/2018-01/10/2021	PhD in Genetics, Oncology and Clinical Medicine (GENOME), XXXIV cycle. Thesis: "The impact of antifibrotic therapy in the management of idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung diseases: a real-world comparative study of efficacy between pirfenidone and nintedanib"

23/04/2021	University of Siena National Scientific Qualification for the role of second-tier University Professor in the competition sector 06 / D1 - Cardiovascular System Diseases and Respiratory System Diseases, SSD MED / 10 (valid until April 23, 2030)
10/12/2014-10/12/2018	Post graduation in Respiratory Diseases (70/70 cum laude) University of Firenze
01/10/2007-23/06/2013	Medical Degree (110/110 cum laude) University of Siena

PERSONAL SKILLS

Mother tongue(s) ITALIAN
Other language(s) ENGLISH

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Spoken production	
EXCELLENT	EXCELLENT	GOOD	GOOD	GOOD

Digital skills

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem solving
GOOD	EXCELLENT	GOOD	GOOD	GOOD

RESEARCH ACTIVITY

Research projects

- ✓ Principal Investigator of the international multicentric project “Exploring the effectiveness and Safety of a reduced dosage of nintedanib in IPF and PPF: a real-world multicenter retrospective observational study” (ESCAPE) in collaboration with Barcelona Clinic, University of Padua and University of Milano Bicocca.
- ✓ Co-Investigator of the national multicentric project “Krebs von den Lungen-6 analysis in a cohort of patients affected with connective tissue disease associated or not with interstitial lung diseases: a multicentric observational prospective study (KASPER)”, in collaboration with 3 Italian Referral Centers for interstitial lung diseases
- ✓ Co-Investigator of the national multicentric project “Krebs von den Lungen-6 as a biomarker of disease progression in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (KRIPTIC)”, in collaboration with 18 Italian Referral Centers for interstitial lung diseases
- ✓ Co-investigator of the project “Harnessing the impact of tezepelumab in patients affected by severe uncontrolled asthma in response to viral infection and allergen stimulation (HYPE)”, approved and funded by AstraZeneca Spa
- ✓ Coordinator for the international multicentric project entitled “Novel autoantibodies for outcome stratification in systemic sclerosis associated interstitial lung disease”, in collaboration with Royal Brompton Hospital (UK) and Medizinische Hochschule Hannover (Germany)
- ✓ Co-investigator of the project entitled “Completing the puzzle: benralizumab effects on adhesion molecules and T regulatory cells imbalance in patients with severe eosinophilic asthma”, approved and funded by AstraZeneca Spa
- ✓ Leader of the projects: “Studio dei livelli plasmatici di CD59s e Periostrina e dell’NO nell’aria esalata come possibili biomarcatori non invasivi nella fibrosi polmonare” and “Studio di biomarcatori prognostici della sarcoidosi nel siero e nel lavaggio broncoalveolare”, selected for “Piano di Ateneo a sostegno della Ricerca (PAR)” 2017 and 2019, University of Siena.
- ✓ Active member of the following projects:
 - “Human Exposomic Determinants of Immune Mediated Diseases (HEDIMED)” Consortium for Asthma - University of Siena
 - “HIDE-IPF”, funded by Regione Toscana, Bando Ricerca Salute 2018 - DD 8245, 26/05/2020
 - “Realizzazione di un percorso clinico-assistenziale per pazienti affetti da asma grave e realizzazione di un network per la ricerca scientifica”, GSK call 2018 - Innovation in severe refractory asthma
 - “Immunocheckpoint inhibitor-related lung toxicity: a multicenter real-life report” - Società Italiana di Pneumologia
 - “Usual interstitial pneumonia in ANCA-associated vasculitis: implication for prognosis” - Società Italiana di Pneumologia.

- "Classification criteria of antisynthetase syndrome" (CLASS Project), endorsed by European League against Rheumatism (EULAR) - American College of Rheumatology (ACR).
- GEN-COVID Multicenter Study

Randomized clinical trials experience:

- ✓ Principal Investigator in 5 RCTs focused on severe asthma, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis and sarcoidosis
- ✓ Sub-Investigator or Co-Investigator in more than 20 international, multicenter RCTs focused on interstitial lung diseases and severe asthma

Certifications

- ✓ Certificate in Essential GCP
- ✓ President of Interstitial Lung Diseases Research Group of Società Italiana di Pneumologia
- ✓ Active member of European Respiratory Society Assembly 12
- ✓ Lecturer of University of Siena for General Practitioners

- Publications
- ✓ Author or coauthor of more than original papers on international peer-reviewed journals
 - ✓ Total citations: 4804; H-index 31
 - ✓ 33 Abstracts accepted and 45 Oral Presentations discussed at national and international scientific congresses

Hereby I declare that what reported above corresponds to the truth (D.P.R. 445/2000)

I authorize the treatment of my personal data according to the current Italian directives (Decreto Legislativo 30 giugno 2003, n. 196)

Siena, 18 December 2024